騰盛博藥-B(2137.HK)高開近15% 安巴韋單抗和羅米司韋單抗聯合療法商業化上市
格隆匯7月7日丨騰盛博藥-B(2137.HK)高開14.84%報10.14港元,市值73.28億港元。公司宣佈,旗下控股公司的長效新冠中和抗體安巴韋單抗和羅米司韋單抗聯合療法在中國商業化上市。首批抗體藥物實現商業放行,標誌着這一聯合療法正式開啟商業化的重要里程碑。安巴韋單抗和羅米司韋單抗聯合療法於2021年12月獲得國家藥品監督管理局(NMPA)上市批准,用於治療輕型和普通型且伴有進展為重型(包括住院或死亡)高風險因素的成人和青少年(12-17歲,體重≥40kg)新型冠狀病毒感染(COVID-19)患者。其中青少年(12-17歲,體重≥40kg)適應證人羣為附條件批准。這也是國產新冠病毒中和抗體聯合治療藥物獲批。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.